Table 2.
Reported Cases of Urinary Tract Infections with Raoultella ornithinolytica
| Author | Year | Age (Yr) | Sex | Comorbidities | Diagnosis | Positive Sample | Identification Technique/Antimicrobial Susceptibility Assessment | Antimicrobial Susceptibility | Treatment | Clinical Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Haruki et al33 | 2014 | 65 | Male | - | Acute prostatis | Blood | Microscan | S: Cefotaxime, levofloxacin R: Piperacillin |
Cefixime then levofloxacin | Recovery |
| Nakasone et al11 | 2015 | 73 | Female | Rheumatoid arthritis (methotrexate) | UTI | Urine | Not specified | S: Ampicillin-sulbactam, amikacin, ceftriaxone, gentamycin, tobramycin, cefepime, ciprofloxacin, nitrofurantoin, ertapenem, piperacillin-tazobactam, trimethoprim/sulfamethoxazole | Empirical oral trimethoprim-sulfamethoxazole for 3 days then oral ciprofloxacin for 5 days | Recovery |
| Previous urosepsis due to CA-ESBL Escherichia coli | ||||||||||
| De Petris et al68 | 2018 | 0 (8 months) | Female | Previous UTI due to E. coli | UTI | Urine | MicroScan | Not specified | Empirical ceftriaxone (60 mg/kg/day) for 3 days then oral cefpodoxime proxetil (5 mg/kg) for a total of 10 days | Recovery |
| Bilateral vesicoureteral reflux | ||||||||||
| Büyükcam et al10 | 2018 | 6 | Female | Hydronephrosis and recurrent UTI | UTI | Urine | MALDI-TOF MS and VITEK®2 (Bioméreux, France) | S: Gentamycin, amoxicillin/clavulanate, piperacillin/tazobactam, cefuroxime, amikacin, ciprofloxacin, ertapenem, imipenem, meropenem, trimethoprim/sulfamethoxazole, ceftazidime, cefixime, cefuroxime axetil, fosfomycin, nitrofurantoin, cefoxitin, ceftriaxone | Cefixime (8 mg/kg/day) for 14 days | Recovery |
Abbreviations: Yr, year; CA-ESBL, community-acquired extended-spectrum ß-lactamase; UTI, urinary tract infection; MALDI-TOF MS, matrix assisted laser desorption ionization-time of flight mass spectrometry; S, susceptible; R, resistant.